Brought to you by 
Boston Scientific acquires Target Therapeutics for $1.1bn
20 Jul 1999
Executive Summary
Boston Scientific has acquired Target Therapeutics (minimally invasive catheters and devices for vascular brain disease) in a stock swap valued at $1.1bn.
Deal Industry
- Medical Devices
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Boston Scientific acquires Target Therapeutics for $1.1bn
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice